https://www.djiboutihealthjournal.com/article/910497076-discure-technologies-appoints-dr-ray-baker-to-its-board-of-directors Djibouti Health Journal en PressRelease 2026-05-05T11:35:00+00:00 Discure Technologies Appoints Dr. Ray Baker to its Board of Directors https://ml.globenewswire.com/media/eb02cf21-747a-4619-8cb2-b3929c46ae7e/small/descure-technologies-logo-png.PNG https://www.djiboutihealthjournal.com/article/910497087-kura-oncology-to-report-first-quarter-2026-financial-results Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Kura Oncology to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.djiboutihealthjournal.com/article/910497096-intellia-therapeutics-to-participate-in-upcoming-investor-conferences Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Intellia Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.djiboutihealthjournal.com/article/910497121-compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-corporate-update Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update  https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.djiboutihealthjournal.com/article/910497160-bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://www.djiboutihealthjournal.com/article/910497222-surgery-partners-inc-announces-first-quarter-2026-results-reaffirms-full-year-2026-guidance Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance https://ml.globenewswire.com/media/d0188456-e6d3-48f9-8479-b40422f00e4c/small/surgerypartnerslinear-1-jpg.jpg https://www.djiboutihealthjournal.com/article/910497278-tris-pharma-appoints-jim-potenziano-ph-d-as-chief-science-and-development-officer Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer https://ml.globenewswire.com/media/2ab6667c-5742-4090-afb8-459cd811c92e/small/logo-png.png https://www.djiboutihealthjournal.com/article/910497407-cytokinetics-announces-positive-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy https://ml.globenewswire.com/media/adcf634e-a2a7-4cdf-98b3-ca658eab1b35/medium/figure-1-assessments-of-kccq-and-pvo2.png https://www.djiboutihealthjournal.com/article/910497479-nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-business-highlights Djibouti Health Journal en PressRelease 2026-05-05T11:30:00+00:00 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png https://www.djiboutihealthjournal.com/article/910497039-what-to-look-for-in-a-deodorant-in-canada-in-2026 Djibouti Health Journal en PressRelease 2026-05-05T11:12:15+00:00 What to Look for in a Deodorant in Canada in 2026 https://ml-eu.globenewswire.com/media/MmU2ZTI3ZDAtOWNkMi00Y2Y4LWE5N2EtZWFiZTg0NGFjZTk0LTEzMjI4ODctMjAyNi0wNS0wNS1lbg==/tiny/Beiersdorf-Canada-Inc-.png https://www.djiboutihealthjournal.com/article/910497392-cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of Djibouti Health Journal en PressRelease 2026-05-05T11:10:00+00:00 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.djiboutihealthjournal.com/article/910497403-uniqure-announces-first-quarter-2026-financial-results-and-provides-recent-company-updates Djibouti Health Journal en PressRelease 2026-05-05T11:05:00+00:00 uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates https://ml.globenewswire.com/media/2ba61fe2-12e5-4a01-afe1-419652b31512/small/logo-uniqure-ms-word-orange-jpg.jpg https://www.djiboutihealthjournal.com/article/910497470-sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook Djibouti Health Journal en PressRelease 2026-05-05T11:03:49+00:00 Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.djiboutihealthjournal.com/article/910497148-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-05T11:01:00+00:00 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.djiboutihealthjournal.com/article/910497078-biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.djiboutihealthjournal.com/article/910497083-dupixent-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910497093-kymera-therapeutics-presents-new-preclinical-ibd-data-for-kt-579-a-first-in-class-oral-irf5-degrader-at-digestive-disease-week Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.djiboutihealthjournal.com/article/910497116-orvida-pharma-to-present-functional-endpoint-development-data-in-rare-palmoplantar-skin-disorders-at-the-83rd-annual-meeting-of-the-society-for Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Orvida Pharma to Present Functional Endpoint Development Data in Rare Palmoplantar Skin Disorders at the 83rd Annual Meeting of the Society for Investigative Dermatology and the 2026 Epidermal Differentiation Disorders Symposium https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg https://www.djiboutihealthjournal.com/article/910497194-editas-medicine-announces-first-quarter-2026-results-and-business-updates Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Editas Medicine Announces First Quarter 2026 Results and Business Updates https://ml.globenewswire.com/media/03686b66-5cbc-40b5-9dfa-be0e7858ac97/small/editas-logo-small-1-jpg.jpg https://www.djiboutihealthjournal.com/article/910497200-climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutaneous-formulation-data-broad-b-cell-mediated-disease-opportunity-and Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.djiboutihealthjournal.com/article/910497206-arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026 Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/563780a0-f8d9-4e37-8665-b622ef2caa5b/small/arvinas-logoart-lg-jpg.jpg https://www.djiboutihealthjournal.com/article/910497213-sotera-health-announces-leadership-transition Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Sotera Health Announces Leadership Transition https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.djiboutihealthjournal.com/article/910497215-relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026 Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 https://ml.globenewswire.com/media/8a986b0a-11c8-4551-b0ad-ec20fe2fe40a/small/relmada-logo-png.png https://www.djiboutihealthjournal.com/article/910497218-fractyl-health-to-report-first-quarter-2026-financial-results-and-provide-business-updates-on-may-12-2026-and-will-participate-in-an-upcoming Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference https://ml.globenewswire.com/media/3a379315-9c07-4655-883e-7e7f26c67778/small/fractyl-logo-png.png https://www.djiboutihealthjournal.com/article/910497220-electra-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ipsoprubart-ela026-in-t-cell-malignancies Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies https://ml.globenewswire.com/media/5c28c3ad-0aec-4979-b6c4-12f1d4bf4c46/small/electra-logo-rgb-png.png https://www.djiboutihealthjournal.com/article/910497226-brewdog-announces-partnership-with-underbelly-as-official-beer-supplier-of-underbelly-at-the-edinburgh-fringe Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 BrewDog Announces Partnership with Underbelly as Official Beer Supplier of Underbelly at the Edinburgh Fringe https://ml.globenewswire.com/media/dc1f57dc-8a83-444e-8722-08f858c451af/medium/brewdog-underbelly.jpeg https://www.djiboutihealthjournal.com/article/910497233-axsome-therapeutics-to-participate-in-upcoming-investor-conferences Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Axsome Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://www.djiboutihealthjournal.com/article/910497236-repligen-reports-first-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://www.djiboutihealthjournal.com/article/910497247-atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026 Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 https://ml.globenewswire.com/media/1506ab30-7618-4ed0-98de-e3815adb3aa6/small/avir-png.png https://www.djiboutihealthjournal.com/article/910497290-seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.djiboutihealthjournal.com/article/910497311-eupraxia-pharmaceuticals-reports-erefs-data-from-its-ongoing-phase-1b-2a-resolve-trial-in-eosinophilic-esophagitis-at-digestive-disease-week-ddw Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.djiboutihealthjournal.com/article/910497313-ocular-therapeutix-reports-first-quarter-2026-financial-results-and-business-highlights Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910497336-rhythm-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-update Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.djiboutihealthjournal.com/article/910497362-nrx-pharmaceuticals-nasdaq-nrxp-announces-initiation-of-commercial-manufacturing-for-preservative-free-ketamine Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.djiboutihealthjournal.com/article/910497386-neuraxis-to-host-first-quarter-2026-results-and-business-update-call-on-tuesday-may-12-2026 Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/a1e3887d-3378-46c5-938d-2b0d5a7c825f/small/neuraxis-logo-png.png https://www.djiboutihealthjournal.com/article/910497398-shopify-delivers-again-as-merchants-clear-100-billion-in-q1-gmv Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Shopify Delivers Again as Merchants Clear $100 Billion in Q1 GMV https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.djiboutihealthjournal.com/article/910497412-cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million Djibouti Health Journal en PressRelease 2026-05-05T11:00:00+00:00 Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.djiboutihealthjournal.com/article/910487809-biontech-ver-ffentlicht-ergebnisse-f-r-das-erste-quartal-2026-sowie-informationen-zur-gesch-ftsentwicklung Djibouti Health Journal en PressRelease 2026-05-05T10:45:00+00:00 BioNTech veröffentlicht Ergebnisse für das erste Quartal 2026 sowie Informationen zur Geschäftsentwicklung https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.djiboutihealthjournal.com/article/910487854-biontech-announces-first-quarter-2026-financial-results-and-corporate-update Djibouti Health Journal en PressRelease 2026-05-05T10:45:00+00:00 BioNTech Announces First Quarter 2026 Financial Results and Corporate Update https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.djiboutihealthjournal.com/article/910488042-diagonal-therapeutics-expands-executive-leadership-team-appoints-industry-veteran-jonathan-piazza-as-chief-financial-officer Djibouti Health Journal en PressRelease 2026-05-05T10:30:00+00:00 Diagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial Officer https://ml.globenewswire.com/media/c2298dfb-0954-43a2-ae2e-866e7a08c7ad/small/diagonallogo-darkcolor-png.png https://www.djiboutihealthjournal.com/article/910487933-new-cda-data-reveals-disconnect-between-knowing-the-risks-of-tanning-and-behaviour-among-gen-z Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 New CDA Data Reveals Disconnect Between Knowing the Risks of Tanning and Behaviour Among Gen Z https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/sun-awareness-month-2026.png https://www.djiboutihealthjournal.com/article/910487988-de-nouvelles-donn-es-de-l-acd-r-v-lent-un-d-calage-entre-la-conscience-de-la-g-n-ration-z-des-risques-li-s-au-bronzage-et-ses-habitudes-de-protection Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 De nouvelles données de l’ACD révèlent un décalage entre la conscience de la génération Z des risques liés au bronzage et ses habitudes de protection solaire https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/mois-de-mai-le-mois-de-la-prudence-au-soleil-2026.png https://www.djiboutihealthjournal.com/article/910488059-paws-itively-paw-litical-voting-opens-for-4th-annual-cutest-pets-on-parliament-hill Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Paws-itively Paw-litical: Voting Opens for 4th Annual Cutest Pets on Parliament Hill https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.djiboutihealthjournal.com/article/910488062-poil-itiquement-patte-tant-le-vote-est-ouvert-pour-le-quatri-me-concours-annuel-les-animaux-de-compagnie-les-plus-mignons-sur-la-colline-du Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Poil-itiquement é-patte-tant : Le vote est ouvert pour le quatrième concours annuel « Les animaux de compagnie les plus mignons sur la Colline du Parlement » https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.djiboutihealthjournal.com/article/910488114-integra-lifesciences-announces-leadership-transition Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Announces Leadership Transition https://ml.globenewswire.com/media/5adce648-cb01-457f-83ba-c7a1895d1515/medium/stuart-essig-chairman-and-chief-executive-officer.png https://www.djiboutihealthjournal.com/article/910488123-fortrea-reports-first-quarter-2026-results Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Fortrea Reports First Quarter 2026 Results https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910488127-aclarion-announces-second-commercial-agreement-with-weill-cornell-medicine Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.djiboutihealthjournal.com/article/910488131-integra-lifesciences-reports-first-quarter-2026-financial-results Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/80d27f1a-2d8e-44f2-92e9-57e14db38652/small/integra-promotional-logos-integra-logo-full-color-process-1.png https://www.djiboutihealthjournal.com/article/910488144-anteris-technologies-announces-first-u-s-patients-treated-in-global-pivotal-paradigm-trial Djibouti Health Journal en PressRelease 2026-05-05T10:00:00+00:00 Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial https://ml.globenewswire.com/media/90a5ae8d-7cf0-4a3d-b38c-f4ad7e3fbf0e/small/anteris-tech-rgb-blue-png.png https://www.djiboutihealthjournal.com/article/910458835-latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting Djibouti Health Journal en PressRelease 2026-05-05T08:00:00+00:00 Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting https://ml-eu.globenewswire.com/media/dc25de9c-07c8-448a-b6af-aea02249e593/medium/global-consensus-on-early-intervention-in-dme.png https://www.djiboutihealthjournal.com/article/910448820-4bio-capital-leads-oversubscribed-61-million-83m-series-a-financing-of-cytospire-therapeutics Djibouti Health Journal en PressRelease 2026-05-05T07:05:00+00:00 4BIO Capital leads oversubscribed £61 million ($83m) Series A financing of Cytospire Therapeutics  https://ml-eu.globenewswire.com/media/fab6412c-5edc-4903-8a71-51e5ccc6accb/small/4bio-capital-logo-png.png https://www.djiboutihealthjournal.com/article/910448817-cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell Djibouti Health Journal en PressRelease 2026-05-05T07:00:00+00:00 Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer https://ml-eu.globenewswire.com/media/99e8d7e3-84e7-41a5-84aa-4f03dcb8e2be/medium/natalie-mount.jpg https://www.djiboutihealthjournal.com/article/910448827-neurocare-ag-mdma-tms Djibouti Health Journal en PressRelease 2026-05-05T07:00:00+00:00 تعلن مجموعة neurocare AG عن ترخيص تسويق الأجهزة الطبية (MDMA) لبيع أجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) في المملكة العربية السعودية https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-tms-therapy-for-depression-with-neurocare-s.jpg https://www.djiboutihealthjournal.com/article/910448841-neurocare-group-ag-announces-mdma-approval-of-tms-devices-in-saudi-arabia Djibouti Health Journal en PressRelease 2026-05-05T07:00:00+00:00 neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-depression-treatment-using-neurocares-apoll.jpg https://www.djiboutihealthjournal.com/article/910448845-novonesis-delivered-strong-start-to-the-year-with-7-organic-sales-growth-in-q1 Djibouti Health Journal en PressRelease 2026-05-05T06:18:16+00:00 Novonesis delivered strong start to the year with 7% organic sales growth in Q1 https://ml-eu.globenewswire.com/media/d0c3bcb0-65ab-400f-9219-15fbf4253148/small/novonesis-logo-1-png.png https://www.djiboutihealthjournal.com/article/910439198-abivax-announces-repurchase-of-royalty-certificates-and-pricing-of-45m-38-5m-offering-of-american-depositary-shares Djibouti Health Journal en PressRelease 2026-05-05T06:00:00+00:00 Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.djiboutihealthjournal.com/article/910429701-santhera-ver-ffentlicht-einladung-zur-ordentlichen-generalversammlung Djibouti Health Journal en PressRelease 2026-05-05T05:00:00+00:00 Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.djiboutihealthjournal.com/article/910429709-santhera-publishes-agenda-for-its-annual-general-meeting Djibouti Health Journal en PressRelease 2026-05-05T05:00:00+00:00 Santhera Publishes Agenda for its Annual General Meeting https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.djiboutihealthjournal.com/article/910410639-axavive-under-investigation-inspecting-the-axon-renewal-anti-aging-benefits-of-the-secret-golden-seed-astragaloside-iv-skin-care-supplement Djibouti Health Journal en PressRelease 2026-05-05T02:59:01+00:00 Axavive Under Investigation: Inspecting the Axon Renewal Anti-Aging Benefits of the Secret Golden Seed Astragaloside IV Skin Care Supplement https://zingfast.com/wp-content/uploads/2026/05/Axavive-Axon-Renewal.jpg https://www.djiboutihealthjournal.com/article/910400806-gl-control-claims-evaluated-investigating-the-ingredients-benefits-for-blood-sugar-trap-support Djibouti Health Journal en PressRelease 2026-05-05T02:26:09+00:00 GL Control Claims Evaluated: Investigating the Ingredients Benefits for Blood Sugar Trap Support https://zingfast.com/wp-content/uploads/2026/05/GL-Control-1.jpg https://www.djiboutihealthjournal.com/article/910400749-vital-wrist-monitor-vital-wrist-ball-under-investigation-evaluating-the-brand-claims-product-benefits Djibouti Health Journal en PressRelease 2026-05-05T01:55:19+00:00 Vital Wrist Monitor & Vital Wrist Ball Under Investigation: Evaluating the Brand Claims & Product Benefits https://zingfast.com/wp-content/uploads/2026/05/Vital-Wrist-Monitor-Vital-Wrist-Ball.jpg https://www.djiboutihealthjournal.com/article/910391392-apa-welcomes-national-focus-on-mental-health-urges-evidence-based-approach-and-continued-focus-on-access-to-care Djibouti Health Journal en PressRelease 2026-05-05T01:41:48+00:00 APA Welcomes National Focus on Mental Health, Urges Evidence-Based Approach and Continued Focus on Access to Care https://ml.globenewswire.com/media/ODc3ZjcyMWMtNDEyOC00Njc4LWE1MzQtNjQ0YzkzNjhiZDI4LTEyNjc0MTAtMjAyNi0wNS0wNS1lbg==/tiny/American-Psychiatric-Associati.png https://www.djiboutihealthjournal.com/article/910391357-axavive-claims-evaluated-the-golden-seed-switch-for-healthy-skin-support Djibouti Health Journal en PressRelease 2026-05-05T01:28:26+00:00 Axavive Claims Evaluated: The Golden Seed Switch for Healthy Skin Support https://zingfast.com/wp-content/uploads/2026/05/Axavive.jpg https://www.djiboutihealthjournal.com/article/910371205-pennant-announces-first-quarter-2026-earnings-release-and-call Djibouti Health Journal en PressRelease 2026-05-04T23:34:37+00:00 Pennant Announces First Quarter 2026 Earnings Release and Call https://ml.globenewswire.com/media/d50f543c-fc54-437d-8007-600644587dfe/small/pennant-logo-png.png https://www.djiboutihealthjournal.com/article/910361255-janell-rae-releases-debut-book-satori-awakening-to-your-truest-self-through-energy-intelligence Djibouti Health Journal en PressRelease 2026-05-04T22:40:00+00:00 Janell Rae Releases Debut Book Satori: Awakening to Your Truest Self Through Energy Intelligence https://pressranger.s3.us-west-1.amazonaws.com/3225770/Janell-Book-Cover-%288%29.png https://www.djiboutihealthjournal.com/article/910351918-ballad-health-invests-15-million-to-expand-robotic-assisted-surgery-earns-national-accreditation-for-quality-and-surgical-excellence Djibouti Health Journal en PressRelease 2026-05-04T22:28:36+00:00 Ballad Health invests $15 million to expand robotic-assisted surgery, earns national accreditation for quality and surgical excellence https://ml.globenewswire.com/media/ODk2ZWQ5ZTQtY2ZhZC00YzBmLTkyNDQtNTg2Y2VhYzgxZTkyLTExMzUxNTItMjAyNi0wNS0wNC1lbg==/tiny/Ballad-Health.png https://www.djiboutihealthjournal.com/article/910351879-elite-pro-force-male-enhancement-gummies-claims-evaluated-the-ultra-peak-horse-gelatin-trick-for-men Djibouti Health Journal en PressRelease 2026-05-04T21:49:17+00:00 Elite Pro Force Male Enhancement Gummies Claims Evaluated: The Ultra Peak Horse Gelatin Trick for Men https://zingfast.com/wp-content/uploads/2026/05/Elite-Pro-Force-Male-Enhancement-Gummies.jpg https://www.djiboutihealthjournal.com/article/910342560-nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study Djibouti Health Journal en PressRelease 2026-05-04T21:29:27+00:00 Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910342587-nanobiotix-annonce-un-amendement-du-protocole-de-l-tude-mondiale-de-phase-3-sur-le-cancer-de-la-t-te-et-du-cou Djibouti Health Journal en PressRelease 2026-05-04T21:29:27+00:00 NANOBIOTIX ANNONCE UN AMENDEMENT DU PROTOCOLE DE L’ÉTUDE MONDIALE DE PHASE 3 SUR LE CANCER DE LA TÊTE ET DU COU https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910342441-jellyfit-claims-evaluated-the-truth-about-jelly-lean-fit-weight-loss-drops-8-ingredients-stacked-with-gelatin-trick-recipe-hack-exposed Djibouti Health Journal en PressRelease 2026-05-04T21:07:11+00:00 JellyFit Claims Evaluated: The Truth About Jelly Lean Fit Weight Loss Drops' 8 Ingredients Stacked with Gelatin Trick Recipe Hack Exposed https://zingfast.com/wp-content/uploads/2026/05/Jelly-Lean-Fit-Weight-Loss-Drops.jpg https://www.djiboutihealthjournal.com/article/910342340-dentsply-sirona-expands-u-s-distribution-footprint-through-enhanced-agreement-with-atlanta-dental-supply Djibouti Health Journal en PressRelease 2026-05-04T21:00:00+00:00 Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.djiboutihealthjournal.com/article/910342356-new-publication-demonstrates-tlx250-px-zircaix-potential-in-diagnosing-kidney-cancers-beyond-ccrcc Djibouti Health Journal en PressRelease 2026-05-04T21:00:00+00:00 New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.djiboutihealthjournal.com/article/910333422-tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-04T20:31:00+00:00 Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d6e37a27-2e33-43bb-ae05-bfb0dedbf190/small/tango-logo-png.png https://www.djiboutihealthjournal.com/article/910333352-teva-to-present-at-the-bofa-securities-health-care-conference Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Teva to Present at the BofA Securities Health Care Conference https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.djiboutihealthjournal.com/article/910333368-vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/dde67700-b1b4-40c4-b930-13bd71804762/small/vor-wordmark-rgb-fullcolor-070920-png.png https://www.djiboutihealthjournal.com/article/910333377-cellectis-to-report-first-quarter-financial-results-on-may-11-2026 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Cellectis to Report First Quarter Financial Results on May 11, 2026 https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.djiboutihealthjournal.com/article/910333384-cellectis-publiera-ses-r-sultats-financiers-du-premier-trimestre-le-11-mai-2026 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026 https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.djiboutihealthjournal.com/article/910333394-olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://www.djiboutihealthjournal.com/article/910333396-crispr-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910333417-jushi-holdings-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Jushi Holdings Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/e65f15fd-322c-4847-83c5-ceafe27f97d5/small/jushi-png.png https://www.djiboutihealthjournal.com/article/910333429-opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg https://www.djiboutihealthjournal.com/article/910333432-eton-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 https://ml.globenewswire.com/media/db07cafa-b35c-4d61-a1a1-d330caf67ad2/small/eton-logo-png.png https://www.djiboutihealthjournal.com/article/910333456-bioage-to-host-r-d-day-focused-on-nlrp3-inhibition-on-may-8-2026 Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.djiboutihealthjournal.com/article/910333491-cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population https://ml.globenewswire.com/media/04c4feba-7841-4ac8-8ca5-6c03be383a0e/small/cvrx-outsmart-the-heart-logo-rgb-blue-png.png https://www.djiboutihealthjournal.com/article/910333578-regional-health-properties-announces-appointment-of-marlie-davis-as-chief-financial-officer Djibouti Health Journal en PressRelease 2026-05-04T20:30:00+00:00 REGIONAL HEALTH PROPERTIES ANNOUNCES APPOINTMENT OF MARLIE DAVIS AS CHIEF FINANCIAL OFFICER https://ml.globenewswire.com/media/bfd51062-4a60-4cf0-9f2f-a4b109b52e4a/small/logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910333399-anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Djibouti Health Journal en PressRelease 2026-05-04T20:15:00+00:00 Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/eb223f66-e7e0-4e0a-94e7-a3f7a06b13ab/small/anaptys-logo-png.png https://www.djiboutihealthjournal.com/article/910333460-coopercompanies-appoints-paul-keel-to-its-board-of-directors Djibouti Health Journal en PressRelease 2026-05-04T20:15:00+00:00 CooperCompanies Appoints Paul Keel to its Board of Directors https://ml.globenewswire.com/media/10a4810f-301c-4d8c-851d-dd09334d10d5/small/coopercompanies-aqua-logo-horz-jpg.jpg https://www.djiboutihealthjournal.com/article/910324477-inspiremd-reports-first-quarter-2026-financial-results Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 InspireMD Reports First Quarter 2026 Financial Results https://ml-eu.globenewswire.com/media/5aefda10-5578-41c7-a1c0-9c4b700687c0/small/inspiremd-jpg.jpg https://www.djiboutihealthjournal.com/article/910324487-option-care-health-to-participate-in-the-bank-of-america-health-care-conference Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 Option Care Health to Participate in the Bank of America Health Care Conference https://ml.globenewswire.com/media/YWM2YTg3MzEtODAyYy00ZmVkLWE5YzUtNDk2YjA4MDU0ZWIxLTEwMTk5NzQtMjAyNi0wNS0wNC1lbg==/tiny/Option-Care-Health-Inc-.png https://www.djiboutihealthjournal.com/article/910324540-kyntra-bio-to-report-first-quarter-2026-financial-results Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 Kyntra Bio to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/9105c1e9-d9e3-4b68-9fc8-261fed7db250/small/kyntra-bio-r-rgb-png.png https://www.djiboutihealthjournal.com/article/910324650-capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12 Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 https://ml.globenewswire.com/media/16ce4387-5b8f-447c-96b8-7c453633f9bf/small/getimage-48-768x274-png.png https://www.djiboutihealthjournal.com/article/910324654-lexicon-pharmaceuticals-announces-100-million-loan-facility-with-hercules-capital Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital https://ml.globenewswire.com/media/afcf3b59-ca71-40ed-9226-a0901bf4d13b/small/logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910324720-aktis-oncology-initiates-phase-1b-clinical-trial-for-aky-2519-a-b7-h3-miniprotein-radioconjugate-in-metastatic-castration-resistant-prostate-cancer Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.djiboutihealthjournal.com/article/910324723-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.djiboutihealthjournal.com/article/910324766-oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates Djibouti Health Journal en PressRelease 2026-05-04T20:05:00+00:00 ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png https://www.djiboutihealthjournal.com/article/910324634-inspire-medical-systems-inc-announces-first-quarter-2026-financial-results-and-updates-2026-guidance Djibouti Health Journal en PressRelease 2026-05-04T20:02:00+00:00 Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance https://ml.globenewswire.com/media/194e83a5-3f7e-4805-88ce-da2e0ab594df/small/inspire-primary-logo-rgb-daylight-002-png.png https://www.djiboutihealthjournal.com/article/910324758-ocugen-announces-private-offering-of-115-million-of-convertible-senior-notes Djibouti Health Journal en PressRelease 2026-05-04T20:01:51+00:00 Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.djiboutihealthjournal.com/article/910324495-praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference Djibouti Health Journal en PressRelease 2026-05-04T20:01:00+00:00 Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.djiboutihealthjournal.com/article/910324509-fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce Djibouti Health Journal en PressRelease 2026-05-04T20:01:00+00:00 FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.djiboutihealthjournal.com/article/910324510-biodesix-announces-first-quarter-2026-results-and-highlights Djibouti Health Journal en PressRelease 2026-05-04T20:01:00+00:00 Biodesix Announces First Quarter 2026 Results and Highlights https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.djiboutihealthjournal.com/article/910324629-hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Djibouti Health Journal en PressRelease 2026-05-04T20:01:00+00:00 Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/M2UyM2ExNWYtYTJjYi00M2RhLTkwZGEtNjZlYTUyMzI4NTI4LTEzMjE4MjEtMjAyNi0wNS0wNC1lbg==/tiny/Hemab-Therapeutics-Inc-.png https://www.djiboutihealthjournal.com/article/910324649-senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Djibouti Health Journal en PressRelease 2026-05-04T20:01:00+00:00 Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.djiboutihealthjournal.com/article/910324596-cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Djibouti Health Journal en PressRelease 2026-05-04T20:00:00+00:00 Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.djiboutihealthjournal.com/article/910324676-providence-saint-john-s-health-center-reinforces-its-commitment-to-maternal-and-newborn-care-through-newly-named-maria-shriver-labor-delivery-and Djibouti Health Journal en PressRelease 2026-05-04T19:42:13+00:00 Providence Saint John’s Health Center Reinforces its Commitment to Maternal and Newborn Care Through Newly Named Maria Shriver Labor, Delivery and Family Wellness Unit https://ml.globenewswire.com/media/7f052405-cf27-4729-904d-589a86a37d33/medium/think-pink-for-women-s-wellness-supporting-providence-saint.jpg https://www.djiboutihealthjournal.com/article/910306648-aegis-treatment-centers-launches-mobile-medication-vehicle-to-expand-access-to-addiction-care-in-pasadena-and-surrounding-areas Djibouti Health Journal en PressRelease 2026-05-04T18:45:00+00:00 Aegis Treatment Centers Launches Mobile Medication Vehicle to Expand Access to Addiction Care in Pasadena and Surrounding Areas https://ml.globenewswire.com/media/ZTNhY2M2NTAtZDZhMy00MDM4LWJmMjEtYzhiYzkwOGIwMDcyLTEyNzQyMTYtMjAyNi0wNS0wNC1lbg==/tiny/Pinnacle-Treatment-Centers.png https://www.djiboutihealthjournal.com/article/910291496-sync-supplement-claims-evaluated-the-revive-daily-sunlight-loophole-formula-for-healthy-circadian-rhythm-support Djibouti Health Journal en PressRelease 2026-05-04T17:18:28+00:00 SYNC Supplement Claims Evaluated: The Revive Daily Sunlight Loophole Formula for Healthy Circadian-Rhythm Support https://zingfast.com/wp-content/uploads/2026/05/SYNC-Supplement.jpg https://www.djiboutihealthjournal.com/article/910291435-sace-launches-out-in-the-open-campaign-for-sexual-violence-awareness-month Djibouti Health Journal en PressRelease 2026-05-04T17:10:11+00:00 SACE Launches “Out in the Open” Campaign for Sexual Violence Awareness Month https://ml.globenewswire.com/media/M2ZhZGI5YjgtZTI2NS00NmY1LTgzYTEtMmFhMTZmNzI3YmM3LTUwMDE2MjA1My0yMDI2LTA1LTA0LWVu/tiny/Sexual-Assault-Center-of-Edmon.png https://www.djiboutihealthjournal.com/article/910291473-eascra-biotech-welcomes-dr-anne-yau-as-life-science-research-scientist Djibouti Health Journal en PressRelease 2026-05-04T17:04:04+00:00 Eascra Biotech Welcomes Dr. Anne Yau as Life Science Research Scientist https://ml.globenewswire.com/media/1eda41c1-8c5d-43f0-9198-b0a1570f47e6/medium/dr-anne-yau.jpg https://www.djiboutihealthjournal.com/article/910278476-confluent-medical-technologies-announces-nitinol-wire-center-of-excellence Djibouti Health Journal en PressRelease 2026-05-04T16:00:00+00:00 Confluent Medical Technologies Announces Nitinol Wire Center of Excellence https://ml.globenewswire.com/media/028bf7c1-4bf6-4b3b-8629-3235829b9477/small/confluent-logo-color-png.png https://www.djiboutihealthjournal.com/article/910272567-when-the-heart-can-t-keep-up-what-to-know-about-heart-failure Djibouti Health Journal en PressRelease 2026-05-04T15:28:08+00:00 When the Heart Can’t Keep Up: What to Know About Heart Failure https://ml.globenewswire.com/Resource/Download/79158b1b-2b4f-4818-8faa-7574106d7290/17877-1.jpg https://www.djiboutihealthjournal.com/article/910272536-timelycare-acquires-alongside-to-expand-continuous-student-support-with-clinician-powered-ai-coaching Djibouti Health Journal en PressRelease 2026-05-04T15:00:00+00:00 TimelyCare Acquires Alongside to Expand Continuous Student Support with Clinician-Powered AI Coaching https://ml.globenewswire.com/media/51377623-fd82-411b-9c2c-22d85af45622/medium/alongside-by-timelycare.png https://www.djiboutihealthjournal.com/article/910272574-awareness-is-key-3-steps-to-help-recognize-stroke-signs-and-risks-for-better-outcomes Djibouti Health Journal en PressRelease 2026-05-04T14:59:07+00:00 Awareness is Key: 3 Steps to Help Recognize Stroke Signs and Risks for Better Outcomes https://ml.globenewswire.com/Resource/Download/71a30026-5d47-467d-b6d5-c5bf1d2b31d8/17855-1.jpg https://www.djiboutihealthjournal.com/article/910266581-flyte-increases-capacity-and-launches-hiring-initiative-as-spirit-airlines-shutdown-disrupts-u-s-air-travel Djibouti Health Journal en PressRelease 2026-05-04T14:30:00+00:00 Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.djiboutihealthjournal.com/article/910266602-chopped-leaf-launches-new-premium-sandwich-lineup-featuring-toasted-ciabatta-creations Djibouti Health Journal en PressRelease 2026-05-04T14:24:08+00:00 Chopped Leaf Launches New Premium Sandwich Lineup Featuring Toasted Ciabatta Creations https://ml.globenewswire.com/media/ZGY0ZWI1OTEtNGNhNy00ZmFjLThhN2EtODM5YTdmNmVkMDUxLTEyNzIxMjEtMjAyNi0wNS0wNC1lbg==/tiny/The-Chopped-Leaf.png https://www.djiboutihealthjournal.com/article/910262632-mmi-s-symani-surgical-system-treats-first-alzheimer-s-patient-in-groundbreaking-remind-study Djibouti Health Journal en PressRelease 2026-05-04T14:10:00+00:00 MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study https://ml.globenewswire.com/media/e9325bed-8fcb-4abf-b66e-6f076014b0fb/small/mmi-logo-stacked-tagline-positive-rgb1-png.png https://www.djiboutihealthjournal.com/article/910262611-research-on-new-class-of-treatments-for-ovarian-cancer-receives-725-000-in-funding-from-ovarian-cancer-canada-to-become-clinical-trial-ready Djibouti Health Journal en PressRelease 2026-05-04T14:00:00+00:00 Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready” https://ml.globenewswire.com/media/YWY2NGZiYWEtODcyZC00Y2I5LThkZGEtYmM5ZjlkYzFkNDMzLTEzMTI5NjUtMjAyNi0wNS0wNC1lbg==/tiny/Ovarian-Cancer-Canada.png https://www.djiboutihealthjournal.com/article/910262626-spring-allergies-hit-lungs-hard-doctor-of-pharmacy-explains-what-actually-helps Djibouti Health Journal en PressRelease 2026-05-04T14:00:00+00:00 Spring Allergies Hit Lungs Hard: Doctor of Pharmacy Explains What Actually Helps https://ml.globenewswire.com/media/13a92186-d8d0-4494-9e0a-5fc1d2e363ee/small/betterbrand-logo-new-png.png https://www.djiboutihealthjournal.com/article/910262571-xpress-wellness-acquires-wichita-s-mental-health-clinic-midwest-counseling-services Djibouti Health Journal en PressRelease 2026-05-04T13:57:00+00:00 Xpress Wellness Acquires Wichita’s Mental Health Clinic Midwest Counseling Services https://ml.globenewswire.com/media/3c8097b3-a387-4dd0-8063-4f48aad75699/small/xpress-wellness-logo-png.png https://www.djiboutihealthjournal.com/article/910258243-cdc-host-tt-certification-for-siemens-healthineers-total-testosterone-test-expands-patient-access-to-gold-standard-equivalent-results Djibouti Health Journal en PressRelease 2026-05-04T13:30:00+00:00 CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results https://ml.globenewswire.com/media/c5f289d1-b23c-41d2-bfe1-0121523d54b6/small/ https://www.djiboutihealthjournal.com/article/910258255-coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026 Djibouti Health Journal en PressRelease 2026-05-04T13:30:00+00:00 Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 https://ml.globenewswire.com/media/07437af0-8ae3-48cf-952b-18bc6b99ca7c/small/coherus-onc-logo-rgb-150-png.png https://www.djiboutihealthjournal.com/article/910258286-alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw Djibouti Health Journal en PressRelease 2026-05-04T13:17:21+00:00 Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910253033-greece-launches-world-s-first-national-wildfire-satellite-system-with-ororatech Djibouti Health Journal en PressRelease 2026-05-04T13:04:00+00:00 Greece Launches World’s First National Wildfire Satellite System with OroraTech https://ml.globenewswire.com/media/f405d4dd-2633-4e23-8086-bbaa6bf83b25/medium/ororatech-s-hellenic-fire-system.jpg https://www.djiboutihealthjournal.com/article/910253114-aura-biosciences-announces-pricing-of-260-million-public-offering-of-common-stock-and-pre-funded-warrants Djibouti Health Journal en PressRelease 2026-05-04T13:03:06+00:00 Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.djiboutihealthjournal.com/article/910252862-carnosyn-brands-expands-tribsyn-applications-across-beverage-dairy-and-medical-nutrition Djibouti Health Journal en PressRelease 2026-05-04T13:00:00+00:00 CarnoSyn® Brands Expands TriBsyn® Applications Across Beverage, Dairy, and Medical Nutrition https://ml.globenewswire.com/media/4b40dd5b-0137-41f8-83de-422e4b4f3196/small/nai-full-logo-green2-0-png.png https://www.djiboutihealthjournal.com/article/910252869-oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer Djibouti Health Journal en PressRelease 2026-05-04T13:00:00+00:00 Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.djiboutihealthjournal.com/article/910252878-curated-digital-health-works-now-there-s-a-claims-study-to-prove-it Djibouti Health Journal en PressRelease 2026-05-04T13:00:00+00:00 Curated Digital Health Works; Now There’s a Claims Study to Prove It https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://www.djiboutihealthjournal.com/article/910252958-biomogging-brings-research-backed-rigour-to-looksmaxxing-as-the-discipline-goes-mainstream Djibouti Health Journal en PressRelease 2026-05-04T13:00:00+00:00 BioMogging Brings Research-Backed Rigour to Looksmaxxing as the Discipline Goes Mainstream https://ml.globenewswire.com/media/70c5dbfa-bae7-4e93-ac79-cd20cb471a59/medium/biomogging-brings-research-backed-rigour-to-looksmaxxing-as.png https://www.djiboutihealthjournal.com/article/910252971-fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and Djibouti Health Journal en PressRelease 2026-05-04T13:00:00+00:00 Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.djiboutihealthjournal.com/article/910253043-gyre-therapeutics-completes-acquisition-of-cullgen-to-create-u-s-and-china-based-fully-integrated-biopharmaceutical-company Djibouti Health Journal en PressRelease 2026-05-04T12:47:47+00:00 Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company https://ml.globenewswire.com/media/24951768-57e9-4d7a-b969-f00258b17136/small/gyre-logo-png.png https://www.djiboutihealthjournal.com/article/910252933-cannabix-technologies-announces-delivery-of-marijuana-breath-test-mbt-to-workplace-drug-and-alcohol-testing-clinic Djibouti Health Journal en PressRelease 2026-05-04T12:45:00+00:00 Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Workplace Drug and Alcohol Testing Clinic https://ml.globenewswire.com/media/72457dcd-4783-441b-b82d-641591cd1f13/medium/cannabix-technologies-inc.jpg https://www.djiboutihealthjournal.com/article/910253010-polyrizon-announces-u-s-patent-expansion-for-its-intranasal-drug-delivery-platform Djibouti Health Journal en PressRelease 2026-05-04T12:45:00+00:00 Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform https://ml.globenewswire.com/media/YWIxMzIzNDgtN2UwNy00NTAyLThjZDMtZWMwNGFjZTdmNWJhLTUwMDEyOTIyMy0yMDI2LTA1LTA0LWVu/tiny/Polyrizon-Ltd-.png https://www.djiboutihealthjournal.com/article/910247536-brainway-launches-personalized-anti-procrastination-app-grounded-in-cbt-earns-6-000-user-reviews Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Brainway Launches Personalized Anti-Procrastination App Grounded in CBT, Earns 6,000+ User Reviews https://ml-eu.globenewswire.com/media/59f7037f-6f10-4f4b-9b8f-6a7b25f61828/medium/brainway-smarter-focus-built-around-you.png https://www.djiboutihealthjournal.com/article/910247553-mapi-pharma-explores-u-s-aseptic-manufacturing-facility-to-support-growing-demand-for-aseptic-and-long-acting-generic-and-innovative-injectables Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Mapi Pharma Explores U.S. Aseptic Manufacturing Facility to Support Growing Demand for Aseptic and Long-Acting Generic and innovative Injectables https://ml.globenewswire.com/media/a15e698a-0f26-4d44-bf6a-78b7ae34d25d/small/mapi-pharma-logo-png.png https://www.djiboutihealthjournal.com/article/910247597-abeona-therapeutics-announces-date-of-first-quarter-financial-results Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Abeona Therapeutics® Announces Date of First Quarter Financial Results https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.djiboutihealthjournal.com/article/910247598-sienna-continues-platform-growth Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Sienna Continues Platform Growth https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.djiboutihealthjournal.com/article/910247606-dentsply-sirona-launches-smart-view-detect-world-s-first-fda-cleared-ai-enabled-diagnostic-aid-for-detecting-teeth-with-periapical-radiolucencies Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Dentsply Sirona Launches Smart View - Detect, World’s First FDA-Cleared AI-enabled diagnostic aid for detecting teeth with Periapical Radiolucencies in CBCTs https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.djiboutihealthjournal.com/article/910247610-fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.djiboutihealthjournal.com/article/910247613-bicara-therapeutics-to-report-first-quarter-2026-financial-results-and-business-updates-on-may-11-2026-at-8-30-am-et Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.djiboutihealthjournal.com/article/910247630-fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/d82bf2ce-81b7-4989-9e6b-08e6bb6e1f95/small/fortressbio1-jpg.jpg https://www.djiboutihealthjournal.com/article/910247674-newgen-provides-update-on-fiscal-year-2025-results-and-strategic-progress Djibouti Health Journal en PressRelease 2026-05-04T12:30:00+00:00 NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress https://ml.globenewswire.com/media/ZWQwY2VjNmQtYTdlZi00YTUxLTg3NmItMmI3OWVkMTQ5MGQ4LTEyOTcwMTEtMjAyNi0wNS0wNC1lbg==/tiny/NewGenIvf-Limited.png https://www.djiboutihealthjournal.com/article/910242525-serefin-health-launches-mycaresteps-program-to-support-care-coordination-across-grey-bruce Djibouti Health Journal en PressRelease 2026-05-04T12:05:00+00:00 Serefin Health Launches MyCareSteps Program to Support Care Coordination Across Grey Bruce https://ml.globenewswire.com/media/NmJiMmQwN2MtYTlmMi00Njc1LTk1N2QtNmZlYzk1MDJkMTc3LTEzMjMwMzktMjAyNi0wNS0wNC1lbg==/tiny/Serefin-Inc.png https://www.djiboutihealthjournal.com/article/910242598-candel-therapeutics-to-host-investor-conference-call-following-presentation-of-extended-data-from-phase-3-trial-of-aglatimagene-besadenovec-in Djibouti Health Journal en PressRelease 2026-05-04T12:05:00+00:00 Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.djiboutihealthjournal.com/article/910242367-proqr-announces-annual-general-meeting-of-shareholders-to-be-held-june-2-2026 Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 https://ml-eu.globenewswire.com/media/f5ae7794-bff7-44dc-8709-0e9c3a9eac77/small/logo-proqr-150x150-png.png https://www.djiboutihealthjournal.com/article/910242370-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/7cf77d4a-25b5-4471-a282-0334907cbfbd/small/falk-logo-rgb-jpg.jpg https://www.djiboutihealthjournal.com/article/910242372-dr-falk-pharma-and-renexxion-announce-positive-results-on-naronapride-in-gastroparesis-from-the-global-phase-2b-move-it-trial Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial https://ml-eu.globenewswire.com/media/540f0a78-db35-42ad-9e90-7b81e8ff3ad6/small/renirl-logo-png.png https://www.djiboutihealthjournal.com/article/910242373-cptx-to-present-preclinical-proof-of-principle-of-its-dna-based-in-vivo-car-t-platform-at-asgct-annual-meeting Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 CPTx to present preclinical proof-of-principle of its DNA-based in vivo CAR T platform at ASGCT Annual Meeting https://ml-eu.globenewswire.com/media/b3ec9ca7-8866-466a-9d91-09342002e341/small/cptx-logo-high-res-png.png https://www.djiboutihealthjournal.com/article/910242419-evaxion-to-announce-business-update-and-first-quarter-2026-financial-results-on-may-7-2026 Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.djiboutihealthjournal.com/article/910242435-recludix-pharma-announces-upcoming-oral-presentations-on-preclinical-data-for-oral-stat6-inhibitor-rex-8756-and-topical-stat-1-3-inhibitors-at-the Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting https://ml.globenewswire.com/media/NDM5ZGUzYTItNGI0Zi00N2Y3LWE3Y2QtZmViNDYyN2I1ZWRjLTEyMzYyMjItMjAyNi0wNS0wNC1lbg==/tiny/Recludix-Pharma-Inc-.png https://www.djiboutihealthjournal.com/article/910242438-rhythm-pharmaceuticals-announces-new-data-presentations-in-acquired-hypothalamic-obesity-at-pediatric-endocrine-society Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.djiboutihealthjournal.com/article/910242442-spur-therapeutics-presents-clinical-insights-on-bone-disease-impact-of-flt201-in-adults-with-gaucher-disease-type-1 Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1 https://ml.globenewswire.com/media/195ccecc-f977-4fb5-ba01-43af7ec47589/small/spur-therapeutics-black-wopacity-rgb-png.png https://www.djiboutihealthjournal.com/article/910242449-kyverna-therapeutics-appoints-nadia-dac-seasoned-commercial-leader-in-neurology-and-rare-disease-as-chief-commercial-officer Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer https://ml.globenewswire.com/media/c166e9f5-941a-48b0-be17-c24d54785784/small/kyverna-primary-full-2-png.png https://www.djiboutihealthjournal.com/article/910242457-4dmt-to-participate-in-upcoming-investor-conferences Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 4DMT to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/027d40cf-145a-47b2-a0b8-823759376823/small/logo-2x-png.png https://www.djiboutihealthjournal.com/article/910242470-valitor-presents-preclinical-data-demonstrating-superior-durability-with-six-month-treatment-protocol-of-vltr-559-to-treat-wet-amd Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Valitor Presents Preclinical Data Demonstrating Superior Durability with Six-month Treatment Protocol of VLTR-559 to Treat Wet AMD https://ml.globenewswire.com/media/58da3c80-c616-4358-9bbe-2936ace96649/small/valitor-sidebyside-png.png https://www.djiboutihealthjournal.com/article/910242492-nanox-announces-distribution-agreement-with-nuviodx-to-support-deployment-of-nanox-arc-systems Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.djiboutihealthjournal.com/article/910242493-bascom-palmer-eye-institute-presents-four-posters-on-rose-bengal-photodynamic-antimicrobial-therapy-at-arvo-2026-advancing-the-clinical-case-for Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis https://ml.globenewswire.com/media/7cd1d796-f4d3-43f7-8e2b-eb51dc04a073/small/new-logo-png.png https://www.djiboutihealthjournal.com/article/910242515-healthlynked-launches-new-consumer-platform-and-multi-site-digital-ecosystem-to-redefine-the-front-door-to-healthcare Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 HealthLynked Launches New Consumer Platform and Multi-Site Digital Ecosystem to Redefine the Front Door to Healthcare https://ml.globenewswire.com/media/d46cdad7-4537-49b8-bd75-54331ac4ff32/small/get-better-faster-png.png https://www.djiboutihealthjournal.com/article/910242538-lifeward-announces-new-rewalk-data-presented-at-asia-2026-conference-demonstrating-a-comprehensive-longitudinal-safety-analysis-for-a-powered Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://www.djiboutihealthjournal.com/article/910242561-lenz-therapeutics-to-report-first-quarter-2026-financial-results-and-recent-corporate-highlights-on-may-11-2026-and-attend-upcoming-investor Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference https://ml.globenewswire.com/media/e058841a-d17f-4fd7-b817-0b2c8e6cb656/small/lenz-png.png https://www.djiboutihealthjournal.com/article/910242564-atsena-presents-positive-interim-six-month-results-from-part-b-of-phase-1-2-3-lighthouse-trial-evaluating-atsn-201-in-patients-with-x-linked Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis https://ml.globenewswire.com/media/90d0bd84-4404-435c-9875-3473b4cc7172/small/atsena-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910242574-after-successful-fda-meeting-clene-filing-accelerated-approval-nda-for-als Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.djiboutihealthjournal.com/article/910242578-akebia-therapeutics-announces-vadadustat-post-hoc-win-statistics-analysis-demonstrating-statistically-significant-reduction-in-mortality-and Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.djiboutihealthjournal.com/article/910242582-legend-biotech-expands-scientific-advisory-expertise-to-inform-future-growth Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth https://ml.globenewswire.com/media/d3a680c2-cab6-4eb2-9ed0-7be055f9e180/small/legend-logo-fullcolor-transparent-1-png.png https://www.djiboutihealthjournal.com/article/910242619-senseonics-enters-into-amended-loan-agreement-with-hercules-to-increase-borrowing-capacity-to-140-million Djibouti Health Journal en PressRelease 2026-05-04T12:00:00+00:00 Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.djiboutihealthjournal.com/article/910237928-emerging-drugs-market-to-reach-558-0-billion-by-2030-driven-by-biologics-innovation-and-regulatory-support Djibouti Health Journal en PressRelease 2026-05-04T11:34:01+00:00 Emerging Drugs Market to Reach $558.0 Billion by 2030, Driven by Biologics Innovation and Regulatory Support https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.djiboutihealthjournal.com/article/910237828-vera-therapeutics-to-participate-in-the-bank-of-america-securities-2026-health-care-conference Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference https://ml.globenewswire.com/media/b5c9081c-e6d9-44f7-abd0-0997a3c713f2/small/vera-thumbnail-jpg.jpg https://www.djiboutihealthjournal.com/article/910237832-macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyz-royalty-purchase-agreement Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement https://ml.globenewswire.com/media/72a7b58c-b7ca-4cd5-b2bb-185124351f1c/small/macrogenics-logo-transparent-background-png.png https://www.djiboutihealthjournal.com/article/910237835-entente-education-canada-honours-dr-roger-wong-with-award-for-eminent-contribution-to-older-adults-in-canada Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 Entente Education Canada honours Dr. Roger Wong with Award for Eminent Contribution to Older Adults in Canada https://ml.globenewswire.com/media/YzNlOWZkNDctZThiZC00MzJjLTg2MmItM2U3ZTNhNzViYzJhLTUwMDE2MjAyOC0yMDI2LTA1LTA0LWVu/tiny/Entente-Education-Canada.png https://www.djiboutihealthjournal.com/article/910237841-bridgebio-to-present-new-acoramidis-data-on-disease-progression-biomarkers-and-clinical-outcomes-at-esc-heart-failure-2026 Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026 https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://www.djiboutihealthjournal.com/article/910237849-kura-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.djiboutihealthjournal.com/article/910237860-palvella-therapeutics-announces-first-patients-dosed-in-phase-2-lotu-trial-of-fast-track-designated-qtorin-rapamycin-for-clinically-significant Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.djiboutihealthjournal.com/article/910237878-inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-liver-microsomes Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes https://ml.globenewswire.com/media/e017df5c-9a9b-4f4f-9a94-6c2eeb0400bc/small/inflarx-logo-png.png https://www.djiboutihealthjournal.com/article/910237911-windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential Djibouti Health Journal en PressRelease 2026-05-04T11:30:00+00:00 Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential https://ml.globenewswire.com/media/Nzk5NDkzNGQtNWZiNi00MGZkLTg2ZTAtYzViNDkwNTJjOTVmLTUwMDEzMTYxMS0yMDI2LTA1LTA0LWVu/tiny/Windward-Bio.png https://www.djiboutihealthjournal.com/article/910237843-cartesian-therapeutics-announces-new-employment-inducement-grants Djibouti Health Journal en PressRelease 2026-05-04T11:05:00+00:00 Cartesian Therapeutics Announces New Employment Inducement Grants https://ml.globenewswire.com/media/2bf78841-be30-4bb5-bfb5-0b5f383f3302/small/cartesian-logo-color-png.png https://www.djiboutihealthjournal.com/article/910237845-nextcure-and-simcere-zaiming-initiate-dose-optimization-for-sim0505-cdh6-adc-in-gynecologic-cancers Djibouti Health Journal en PressRelease 2026-05-04T11:05:00+00:00 NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers https://ml.globenewswire.com/media/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4/small/logo-nextcure-jpg.jpg https://www.djiboutihealthjournal.com/article/910237870-kraig-biocraft-laboratories-launches-april-may-production-cycle-following-record-spider-silk-output Djibouti Health Journal en PressRelease 2026-05-04T11:05:00+00:00 Kraig Biocraft Laboratories Launches April/May Production Cycle Following Record Spider Silk Output https://ml.globenewswire.com/media/3cf5ab91-0822-460b-bb13-17447941c84a/small/kblb-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910233626-pasithea-therapeutics-announces-appointment-of-kartik-krishnan-m-d-ph-d-as-chief-medical-officer Djibouti Health Journal en PressRelease 2026-05-04T11:01:00+00:00 Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer https://ml.globenewswire.com/media/0016f128-13c3-45a7-8455-cec1f4768995/small/pasithealogo-png.png https://www.djiboutihealthjournal.com/article/910233519-ardena-strengthens-executive-team-to-drive-its-next-phase-of-growth Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Ardena Strengthens Executive Team to Drive its Next Phase of Growth https://ml-eu.globenewswire.com/media/eddef504-18ee-4f10-8442-9e61ef77e262/medium/ardena-appoints-cfo-and-cco.png https://www.djiboutihealthjournal.com/article/910233520-indivior-announces-175-million-accelerated-share-repurchase Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Indivior Announces $175 Million Accelerated Share Repurchase https://ml-eu.globenewswire.com/media/42de3285-90ea-4020-a3ad-25f71026b41a/small/indivior-logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910233590-biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.djiboutihealthjournal.com/article/910233621-tenax-therapeutics-appoints-timothy-healey-mba-as-chief-commercial-officer Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer https://ml.globenewswire.com/media/d8c1d3b1-51a5-4835-a9e8-6d5bce14917e/small/tenax-logo-rgb-color-jpg.jpg https://www.djiboutihealthjournal.com/article/910233623-netramark-appoints-dr-panteli-theocharous-as-fractional-chief-medical-officer-strengthening-clinical-leadership-to-accelerate-global-adoption-of Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI https://ml.globenewswire.com/media/d65cf3f8-cf9c-475c-b740-09a659269da4/small/netramark-word-eye-blk-jpg.jpg https://www.djiboutihealthjournal.com/article/910233629-krystal-biotech-announces-first-quarter-2026-financial-and-operating-results Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Krystal Biotech Announces First Quarter 2026 Financial and Operating Results https://ml.globenewswire.com/media/94ec1f39-c0eb-4e65-9d7e-250519ef03f4/small/krys-logo-nobackground-with-registered-symbol-png.png https://www.djiboutihealthjournal.com/article/910233642-10-barrel-brewing-launches-clean-slate-and-salty-sips-expanding-rtd-line-with-functional-n-a-and-low-sugar-cocktails Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 10 Barrel Brewing Launches Clean Slate and Salty Sips, Expanding RTD Line with Functional N/A and Low-Sugar Cocktails https://ml.globenewswire.com/media/5e71b27b-1cc8-4780-8689-8d8d6ae86236/medium/clean-slate-and-salty-sips.png https://www.djiboutihealthjournal.com/article/910233645-seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.djiboutihealthjournal.com/article/910233649-centrum-launches-newly-reformulated-adults-50-complete-multivitamin-with-clinically-shown-cognitive-benefits Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Centrum Launches Newly Reformulated Adults 50+ Complete Multivitamin with Clinically Shown Cognitive Benefits https://ml.globenewswire.com/media/395df94a-8079-4f58-9b54-df434e56ec33/medium/centrum-adults-50-complete-multivitamin.png https://www.djiboutihealthjournal.com/article/910233653-centrum-lance-sa-multivitamine-compl-te-adultes-50-nouvellement-reformul-e-avec-des-bienfaits-cognitifs-d-montr-s-cliniquement Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Centrum lance sa multivitamine complète Adultes 50+ nouvellement reformulée avec des bienfaits cognitifs démontrés cliniquement https://ml.globenewswire.com/media/abbbfaf3-e52b-413c-9ded-52f74cf50911/medium/centrum-multivitamine-complete-pour-adultes-50.png https://www.djiboutihealthjournal.com/article/910233661-genyro-announces-new-paper-demonstrating-how-sidewinder-technology-democratizes-dna-construction-at-scale-and-facilitates-ai-driven-protein-design Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Genyro Announces New Paper Demonstrating How Sidewinder Technology Democratizes DNA Construction at Scale and Facilitates AI-Driven Protein Design https://ml.globenewswire.com/media/346f123b-cc5d-4de0-a31f-9c4f1315c070/medium/genyro-co-founders.jpg https://www.djiboutihealthjournal.com/article/910233678-seer-announces-appointment-of-anthony-bazarko-as-chief-commercial-officer Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer https://ml.globenewswire.com/media/ecdddbc3-8a58-4cba-a4a1-33971e79339a/medium/anthony-bazarko.jpg https://www.djiboutihealthjournal.com/article/910233683-istios-health-partners-with-care-id-to-expand-national-infectious-disease-clinical-research-network Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Istios Health Partners with CARE-ID to Expand National Infectious Disease Clinical Research Network https://ml.globenewswire.com/media/MTI0OGVmYTMtNmZkNC00ODA4LWJlNzUtNTYxODJlODcxNDBmLTEzMTYxMjEtMjAyNi0wNS0wNC1lbg==/tiny/Istios-Health.png https://www.djiboutihealthjournal.com/article/910233687-adma-biologics-announces-fda-approval-to-expand-the-label-for-asceniv-to-include-pediatric-immune-compromised-patients-two-years-of-age-and-older Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg https://www.djiboutihealthjournal.com/article/910233701-axsome-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update Djibouti Health Journal en PressRelease 2026-05-04T11:00:00+00:00 Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://www.djiboutihealthjournal.com/article/910233704-cabaletta-bio-announces-pricing-of-150-million-underwritten-offering Djibouti Health Journal en PressRelease 2026-05-04T10:35:54+00:00 Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering https://ml.globenewswire.com/media/44175396-6bbb-435f-b037-54a4052160d4/small/cabaletta-bio-registered-logo-png.png https://www.djiboutihealthjournal.com/article/910224348-aura-biosciences-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants Djibouti Health Journal en PressRelease 2026-05-04T10:03:00+00:00 Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.djiboutihealthjournal.com/article/910224335-aura-biosciences-announces-ceo-transition-as-company-advances-phase-3-compass-trial-toward-enrollment-completion Djibouti Health Journal en PressRelease 2026-05-04T10:01:00+00:00 Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.djiboutihealthjournal.com/article/910224339-holland-bloorview-kids-rehabilitation-hospital-receives-475-000-commitment-from-td-bank-group-to-support-youth-with-disabilities Djibouti Health Journal en PressRelease 2026-05-04T10:00:00+00:00 Holland Bloorview Kids Rehabilitation Hospital receives $475,000 commitment from TD Bank Group to support youth with disabilities https://ml.globenewswire.com/media/YjY1NmY0MjktNjNkNy00MjI4LTgwNDYtZWJjZmRmYTgyZmI0LTExMDQ5NDUtMjAyNi0wNS0wNC1lbg==/tiny/Holland-Bloorview-Kids-Rehabil.png https://www.djiboutihealthjournal.com/article/910224345-scilex-holding-company-announces-its-board-of-directors-approved-may-26-2026-as-the-payment-date-of-the-previously-announced-dividend-of-dream-bowl Djibouti Health Journal en PressRelease 2026-05-04T10:00:00+00:00 Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the… https://ml.globenewswire.com/media/e2f985bf-0880-4d05-8838-90a69c888cf9/small/logo-jpg.jpg https://www.djiboutihealthjournal.com/article/910220606-mother-s-day-gifting-is-changing-from-symbolic-presents-to-meaningful-relief-bob-and-brad-marks-the-occasion-with-up-to-30-off-wellness-devices Djibouti Health Journal en PressRelease 2026-05-04T09:10:38+00:00 Mother’s Day Gifting Is Changing: From Symbolic Presents to Meaningful Relief — Bob and Brad Marks the Occasion with Up to 30% Off Wellness Devices https://ml.globenewswire.com/media/b55bca4c-0fac-4226-9f7d-2e4b7b3e94e0/medium/mother-s-day-gifts-2026.png https://www.djiboutihealthjournal.com/article/910150844-novelty-nobility-taps-agc-biologics-to-further-develop-bispecific-drug-candidate Djibouti Health Journal en PressRelease 2026-05-04T00:00:00+00:00 Novelty Nobility Taps AGC Biologics to Further Develop Bispecific Drug Candidate https://ml.globenewswire.com/media/cecf4f80-22df-4bbf-b0a7-f50b9acf9495/medium/agc-biologics-and-novelty-nobility-representatives-meet.png https://www.djiboutihealthjournal.com/article/910150881-agc Djibouti Health Journal en PressRelease 2026-05-04T00:00:00+00:00 ノベルティ・ノビリティ、AGCバイオロジクスと提携し、二重特異性抗体候補薬の開発を推進 https://ml.globenewswire.com/media/NWUzMzQxMTYtZjcyYS00YjQ4LWE2ODYtY2ZiNWE0YTlmM2MzLTEzMTU5MjMtMjAyNi0wNS0wNC1qYQ==/tiny/AGC-Biologics-Inc-.png https://www.djiboutihealthjournal.com/article/910150885-novelty-nobility-agc-biologics Djibouti Health Journal en PressRelease 2026-05-04T00:00:00+00:00 노벨티 노빌리티 (Novelty Nobility), 이중특이성 항체 개발 위해 AGC Biologics와 협력 확대 https://ml.globenewswire.com/media/NWUzMzQxMTYtZjcyYS00YjQ4LWE2ODYtY2ZiNWE0YTlmM2MzLTEzMTU5MjMtMjAyNi0wNS0wNC1rbw==/tiny/AGC-Biologics-Inc-.png